About us.
What we do.
Sareum is a clinical-stage small molecule company actively involved in developing next generation kinase inhibitors to treat autoimmune diseases and cancer.
At Sareum, we recognise the crucial role of the TYK/JAK cell signalling family in maintaining a healthy immune system, and our pipeline is primarily focused on this area of scientific and commercial interest.
Our most advanced internal program, SDC-1801, is a potent and selective TYK2/JAK1 inhibitor designed to address autoimmune diseases with a particular focus on psoriasis.
Sareum’s second product SDC-1802 is a TYK2/JAK1 inhibitor being developed for cancer and cancer immunotherapy applications.
Sareum also has a significant economic interest in SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Our strategy.
At Sareum, we are committed to advancing molecules in the TYK2/JAK1 space for the treatment of autoimmune diseases and cancer. Our focus on this dual JAK kinase inhibition is due to the potential superior efficacy we believe this offers compared to agents targeting just one of these kinases.
With our highly experienced team, we specialise in kinase inhibition and have decades of experience in R&D and public company management. Our approach is to discover and develop programmes to late preclinical, or early clinical, stages before licensing or partnering, maximising the return on our investment.
Our ultimate goal is to generate revenue by licensing our innovative drug development programmes to pharmaceutical partners, allowing us to bring these therapies to market and improve patient outcomes.
How we work.
Sareum welcomes partnering opportunities to bring our innovative drug development programmes to patients. We collaborate with trusted providers to achieve optimal outcomes for our investors and our Company.
Our in-house team maintains a lean cost base, while engaging laboratory-based research and development fee-for-service organisers, giving us access to a global network of expert research providers.
Contact us to learn more about our approach and how we can work together to make a meaningful impact.
Sareum board.